ClinicalTrials.gg
CompletedNCT04020185Updated Dec 11, 2024Results posted

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

A Phase 1/2 interventional study of IMSA101 and Immune checkpoint inhibitor (ICI) in Solid Tumor, Adult, sponsored by ImmuneSensor Therapeutics Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by ImmuneSensor Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)

Read the detailed description

This is an open-label, dose escalation (Phase I), and dose expansion (Phase IIA) study designed to evaluate safety and efficacy of IMSA101 alone or in combination with an ICI (Phase I and II). Therefore, the study will be conducted in 2 phases. The dose of IMSA101 in Phase IIA will be based on the monotherapy and combination Recommended Phase 2 Doses (RP2Ds) from Phase I.

The following methodology applies to all patients (unless otherwise indicated):

  • Pre-treatment screening radiographic tumor assessments will be collected within 30 days prior to initial dose for all patients. Photographic assessments for cutaneously-accessible lesions will be performed as detailed in a separate photography manual.
  • Treatment cycles will be 28 days in duration with lesions injected weekly on Day 1 for the first three weeks of Cycle 1 and then every 2 weeks during cycles 2 and beyond.
  • A single pre-defined lesion/lesion site (longest diameter ≥ 10 mm and ≤ 35 mm) shall be injected throughout study duration, if possible. Where the original injection site is considered by the investigator to become inaccessible, a second lesion/lesion site shall be selected as a replacement and this shall be used henceforth so long as it is considered accessible. Subsequent injection sites shall be replaced when they are considered inaccessible.
  • Where no remaining accessible lesions are present and where benefit of IMSA101 therapy is, in the opinion of the investigator, being derived by the patient, continued injections of IMSA101 into the vicinity of an inaccessible lesion or, in the case that a lesion can no longer be radiographically visualized, into the last known location of the non-visible lesion shall be allowed.
  • Patients will be admitted to the hospital for observation overnight following IT injection with IMSA101 on Day 1 of Cycle 1. Patients will be followed throughout the study for drug tolerability and safety by collection of clinical and laboratory data, including information on adverse events (AEs) using CTCAE v5.0 criteria, serious adverse events (SAEs), DLTs, concomitant medications, vital signs, and electrocardiograms (ECGs).
  • Patients will be assessed for anti-tumor efficacy based on radiographic assessments and if applicable, photographic tumor assessments, and analysis of Objective Response Rate (ORR), Time to Progression (TTP), and Progression Free Survival (PFS) using RECIST criteria (Appendix 13.2) at screening and the end (≤ 7 days) of even numbered cycles (Cycle 2, Cycle 4, etc.) after the first dosing.
02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

ImmuneSensor Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and mental capability to understand the informed consent
  2. Male or female patients > 18 years of age
  3. or cytologically documented locally advanced or solid tumor to or otherwise ineligible for treatment with standard-of-care agents/regimens, including but not limited to:

    • Malignant melanoma
    • Hormone receptor negative breast cancer
    • Gastro-esophageal cancer
    • Non-small cell lung cancer
    • Head and neck cancer
    • Hepatoma
    • Renal cell carcinoma
  4. (ECOG) performance status of ≤ 1
  5. Evaluable or as follows:

    • A minimum of 3 -evaluable lesions: one that is suitable for injection and biopsied; one non-injected that will be biopsied for abscopal effect; and one measurable lesion that will be followed for response only.
    • Injectable tumors shall be accessed by intralesional (cutaneous) or percutaneous injection only, including those lesions that are visible, palpable, or detectable by standard radiographic or ultrasound methods. Neither surgical procedures nor endoscopically-guided injections including those to endobronchial, endoluminal, or endosinusial spaces shall be allowed. While no anatomic locations are required or disallowed, lesions selected for intratumoral injection must, in the opinion of the investigator:
    • Not be immediately adjacent to blood vasculature or other physiologic landmarks in such a way that will accrue undue safety risk to the patient
    • Have longest diameter ≥ 10 mm and ≤ 50 mm
    • Be fully efficacy evaluable per RECIST v1.1 criteria
  6. > 3 months (Phase I) and > 6 months (Phase IIA)
  7. without evidence of conduction abnormalities or active ischemia as determined by the investigator
  8. Acceptable organ and marrow function as defined below:

    • > 1,500 cells/μL
    • > 50,000 cells/μL
    • Total ≤ 1.5 times the (ULN)
    • (AST)/alanine transaminase (ALT) ≤ 2.5 times ULN. If liver metastases are present, AST/ALT \< 5 times ULN
    • Serum creatinine \< 1.5 mg/dL and a measured ≥ 50 mL/min using the Cockcroft-Gault formula
    • (PT)/partial thromboplastin time (PTT) ≤ 1.5 times ULN
  9. Women of (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or is not (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test prior to first dose of study drug
  10. Male and female patients with must agree to use two forms of highly effective throughout the study
  11. Phase I combination only: Demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved or PD-L1 targeted ICI with no Grade ≥ 3 events considered by the investigator to be drug-related.

Exclusion criteria

Exclusion Criteria:

  1. Anti-cancer therapy within 4 weeks or \< 5 half-lives of the first dose of study drug.
  2. Failure to recover to Grade 1 or less from AEs due to prior anti-cancer therapy.
  3. Known untreated or treated brain metastases that have not been stable (scan showing no worsening of central nervous system (CNS) lesion[s] and no requirement of ) ≥ 4 weeks prior to study enrollment
  4. Baseline prolongation of /QTc interval (QTc interval > 470)
  5. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in opinion of the investigator would limit compliance with study requirements
  6. Women who are pregnant or breastfeeding
  7. Phase I combination only: Prior tumor progression through or PD-L1 targeted ICI therapy.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Ph I Monotherapy

    * Dose escalation design in which administered dose levels of IMSA101 as monotherapy will be escalated stepwise in successive cohorts of 3 to 6 patients per dose group (using a standard 3+3 study design) of IMSA101 until the RP2D or maximum tolerated dose (MTD) level is identified. * The first patient enrolled in each dose level must complete the first two weeks of Cycle 1 prior to enrolling the second and third patients. * Dose levels to be evaluated include (although not necessarily limited to) 100 µg (representing 1/60th of the pre-clinical Highest Non-Severely Toxic Dose \[HNSTD\] dose), 200 µg, 400 µg, 800 µg, and 1,200 µg.

    Drug: IMSA101

  • Experimental
    Ph I Combination Therapy

    * Ph I combination dosing of IMSA101 shall be evaluated upon satisfaction of the following criteria: * A given dose level (combo dose level 1) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT). * The next higher dose level (combo dose level 2) has been confirmed as safe for monotherapy dosing (i.e. 2/6 patients experience Cycle 1 DLT). * The dose level (combo dose level 1) is found to demonstrate adequate IMSA101 pharmacodynamic (PD) activity based on exploratory endpoints. * Eligible patients shall have demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1/PD-L1-targeted ICI with no Grade ≥ 3 CTCAE events considered to be drug-related. * Safety evaluations and dose escalation of IMSA101 administered in combination with current therapy shall proceed in a manner consistent with monotherapy escalation and shall proceed independently of monotherapy dose escalation.

    Drug: IMSA101 · Drug: Immune checkpoint inhibitor (ICI)

  • Experimental
    Ph II Monotherapy (Arm A)

    * This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as monotherapy * Tumor type to be evaluated will be identified prior to Phase IIA commencement and will be documented in a protocol amendment.

    Drug: IMSA101

  • Experimental
    Ph II Combination Therapy (Arm B)

    * This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with PD-1/PD-L1 targeted immune checkpoint inhibitors. * This arm shall include a safety run-in of 5-10 patients. * Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment.

    Drug: IMSA101 · Drug: Immune checkpoint inhibitor (ICI)

  • Experimental
    Ph II Combination Therapy (Arm C)

    * This dose-expansion arm of 20 patients is intended to confirm the tolerability of the RP2D and identify provocative signals of IMSA101 anti-tumor activity when administered as combination therapy with non-PD-1/PD-L1-targeted immuno-oncology (IO) drugs approved by the FDA. * This arm shall include a safety run-in of 5-10 patients. * Tumor type and corresponding treatment combination will be identified prior to Phase IIA commencement and documented in a protocol amendment..

    Drug: IMSA101 · Drug: Immuno-oncology (IO) therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities

    Highest dose level of IMSA101 at which no more than 1 out of 6 patients experienced a dose limiting toxicity (DLT) during the first cycle (28 days) of therapy.

    Time frame: Cycle 1 (28 days) of therapy

Secondary outcomes

  1. Best Overall Response

    The sum of number of patients with best overall response (complete response, partial response, stable disease or progressive disease) as per RECIST v1.1 until End of Treatment. Tumor response was evaluated at the end of each even numbered cycle (eg. Cycle 2, Cycle 4, etc.) until End of Treatment.

    Time frame: 9 months

07

Results

Posted Dec 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneMonotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μg
Started43447477
Completed32324445
Not completed11123032
Withdrew: Death00121010
Withdrew: Consent withdrawn10002011
Withdrew: Patient in hospice01000000
Withdrew: Continuing on expanded access00000011

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities

Highest dose level of IMSA101 at which no more than 1 out of 6 patients experienced a dose limiting toxicity (DLT) during the first cycle (28 days) of therapy.

Time frame:
Cycle 1 (28 days) of therapy
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities
ParticipantsMonotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μg
Number of Participants With Dose-Limiting Toxicities00000010
Statistical analysis
  • Monotherapy 100 μg vs Monotherapy 200 μg vs Monotherapy 400 μg vs Monotherapy 800 μg vs Monotherapy 1200 μg vs Combination Therapy 800 μg vs Combination Therapy 1200 μg vs Combination Therapy 2400 μg · Maximum tolerated dose (monotherapy): 1200
SecondaryBest Overall Response

The sum of number of patients with best overall response (complete response, partial response, stable disease or progressive disease) as per RECIST v1.1 until End of Treatment. Tumor response was evaluated at the end of each even numbered cycle (eg. Cycle 2, Cycle 4, etc.) until End of Treatment.

Time frame:
9 months
Reported as:
Count of participants · Participants
Best Overall Response
ParticipantsMonotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μg
Complete Response00000000
Partial Response00000010
Stable Disease00100101
Progressive Disease43226343
Not Evaluable00000000

Adverse events

Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monotherapy 100 μg0/4 (0%)2/4 (50%)4/4 (100%)
Monotherapy 200 μg0/3 (0%)1/3 (33.3%)3/3 (100%)
Monotherapy 400 μg1/4 (25%)2/4 (50%)4/4 (100%)
Monotherapy 8002/4 (50%)3/4 (75%)3/4 (75%)
Monotherapy 12001/7 (14.3%)1/7 (14.3%)7/7 (100%)
Combination Therapy 800 μg0/4 (0%)1/4 (25%)4/4 (100%)
Combination Therapy 1200 μg1/7 (14.3%)5/7 (71.4%)7/7 (100%)
Combination Therapy 24000 μg0/7 (0%)5/7 (71.4%)7/7 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventMonotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800Monotherapy 1200Combination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 24000 μg
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/41/30/40/40/70/40/70/7
Disease progressionGeneral disorders0/40/30/41/41/70/42/70/7
DysphagiaGastrointestinal disorders0/40/30/41/40/70/40/70/7
Inguinal herniaGastrointestinal disorders1/40/30/40/40/70/40/70/7
Malignant bowel obstructionGastrointestinal disorders0/40/31/40/40/70/40/70/7
PyrexiaGeneral disorders1/40/30/40/40/70/40/70/7
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/30/41/40/70/40/70/7
Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40/30/40/40/70/40/70/7
PneumoniaInfections and infestations1/40/30/40/40/70/40/70/7
Extradural haematomaInjury, poisoning and procedural complications0/40/31/40/40/70/40/70/7
Most frequent other events
Showing 10 of 150
Most frequent other events
EventMonotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800Monotherapy 1200Combination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 24000 μg
FatigueGeneral disorders1/43/33/41/43/71/43/75/7
Decreased appetiteMetabolism and nutrition disorders0/43/30/40/41/71/43/74/7
Injection site painGeneral disorders1/41/31/40/45/73/41/70/7
VomitingGastrointestinal disorders2/40/30/40/41/70/45/71/7
PyrexiaGeneral disorders2/40/30/40/40/70/42/74/7
DyspnoeaRespiratory, thoracic and mediastinal disorders1/40/32/40/41/71/43/74/7
DiarrhoeaGastrointestinal disorders2/40/30/40/41/71/42/72/7
AstheniaGeneral disorders0/40/32/40/40/70/41/73/7
DysphagiaGastrointestinal disorders0/40/30/42/40/70/40/71/7
HeadacheNervous system disorders0/41/32/40/41/70/43/73/7

Baseline characteristics

Patients who received at least 1 dose of IMSA101.

Age, Categorical
Age, Categorical(Participants)Monotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μgTotal
<=18 years000000000
Between 18 and 65 years3311317322
>=65 years1033430418
Age, Continuous
Age, Continuous(years)Monotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μgTotal
Mean56.5 ± 12.0153.7 ± 2.0866.5 ± 4.1264.8 ± 6.9565.0 ± 14.2974.0 ± 11.3450.3 ± 10.8963.0 ± 21.5361.4 ± 14.12
Sex: Female, Male
Sex: Female, Male(Participants)Monotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μgTotal
Female1032523622
Male3312224118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Monotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μgTotal
Hispanic or Latino101000327
Not Hispanic or Latino3233734530
Unknown or Not Reported010101003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Monotherapy 100 μgMonotherapy 200 μgMonotherapy 400 μgMonotherapy 800 μgMonotherapy 1200 μgCombination Therapy 800 μgCombination Therapy 1200 μgCombination Therapy 2400 μgTotal
American Indian or Alaska Native000000000
Asian000010012
Native Hawaiian or Other Pacific Islander001000001
Black or African American000110002
White3112544626
More than one race010000102
Unknown or Not Reported112100207
08

Study locations

6 sites
  • Honor Health
    Scottsdale, Arizona 85260, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Atlantic Health System/Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Sep 2023, 47 months.

Results were first posted in Dec 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 15, 2019
StartActual
Sep 23, 2019
Primary completionActual
Sep 15, 2023
CompletionActual
Sep 15, 2023
Results first posted
Dec 11, 2024
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04020185
Lead sponsor
ImmuneSensor Therapeutics Inc.
Responsible party
Sponsor
First posted
Jul 15, 2019
Start date
Sep 23, 2019
Primary completion
Sep 15, 2023
Completion
Sep 15, 2023
Results posted
Dec 11, 2024
Last update
Dec 11, 2024

Study contacts

Teresa S Mooneyham
study director · Vice President, ImmuneSensor Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STING Agonist IMSA101

Start the discussion